Xenetic Biosciences, Inc. 2025 Annual Report: Key Points, Strategic Review, and Risks for Investors

Introduction

Xenetic Biosciences, Inc. (Nasdaq: XBIO), a clinical-stage biopharmaceutical company, has released its 2025 Annual Report on Form 10-K. The report contains significant information relevant to shareholders and potential investors, including a strategic review, ongoing business risks, and the company’s financial and technological status. Below is an in-depth analysis of the key points, focusing on issues that may be price sensitive and could impact the company’s share value.

Key Highlights from the 2025 Annual Report

1. Ongoing Strategic Review Process

• Formal Strategic Review Initiated: Xenetic has commenced a formal strategic review process, with the assistance of external financial and legal advisors. The company is exploring a wide range of strategic alternatives to maximize shareholder value. These alternatives include, but are not limited to, the sale of all or part of the company or its assets, business combinations such as a reverse merger, share exchange, or similar transactions.
• Engagement with Third Parties: An independent committee of the Board has already engaged in preliminary discussions with third parties regarding potential transactions. There is currently no deadline or definitive timetable for the completion of this process, and no assurance that any proposal will be made, accepted, or consummated.
• Potential Impact: Any completed transaction could have a significant impact on current shareholders. Notably, a transaction could result in current investors of the counterparty holding a substantial majority of Xenetic’s outstanding common stock post-transaction, which may lead to dilution or significant changes in control.

2. Financial Position and Funding Requirements

• Operating Losses and Accumulated Deficit: As of December 31, 2025, Xenetic reports an accumulated deficit of approximately \$199.9 million. The company has never been profitable, expects significant additional operating losses as it expands R&D and commercialization efforts, and may never achieve profitability.
• Substantial Additional Funding Needed: The company will require substantial additional capital to achieve its goals, particularly for R&D and regulatory approval of its drug candidates. Failure to obtain necessary funding on acceptable terms—or at all—could force Xenetic to delay, limit, or terminate product development, other operations, or commercialization efforts.
• Risk of Dilution or Restrictive Terms: Raising additional capital may result in significant dilution for existing shareholders, operational restrictions, or the relinquishment of rights to key technologies or drug candidates.
• Nasdaq Listing Compliance: There is a risk that Xenetic may not continue to meet the continued listing requirements of the Nasdaq Capital Market, which could result in a delisting of its common shares, further impacting share liquidity and value.

3. Business Model, Technology & Pipeline

• Focus on DNase Platform Technology: The company’s primary focus is the development of its DNase platform technology, which is in early-stage development. Xenetic’s business is substantially dependent on the success of this technology.
• Collaborative Model: The company operates under a collaborative development model, working with biotechnology and pharmaceutical partners, as well as academic institutions, to progress its pipeline. Under these agreements, Xenetic retains rights for major markets and co-owns clinical data, which can inform future decisions about commercialization.
• Significant Partnerships: Collaborations with Scripps Research, PeriNess, and the University of Virginia (UVA) are highlighted as key partnerships for technology development and potential pipeline expansion.
• Early Stage and High Uncertainty: Xenetic is classified as an early-stage company in the business of developing pharmaceutical products. There is significant uncertainty around whether these development efforts will ever materialize into commercial products or generate value for investors.

4. Principal Risks and Uncertainties

• Strategic Review Outcomes: The outcome and timing of the ongoing strategic review process are uncertain. The Board may ultimately decide not to pursue any strategic alternative, or may be unable to consummate any proposed transaction due to market, regulatory, or other factors. Announcing or failing to consummate a transaction could disrupt business operations and negatively affect the stock price.
• Going Concern and Capital Risks: The company’s future is highly dependent on raising additional working capital. If it fails to do so, there are risks to its ability to continue as a going concern.
• Regulatory and Commercialization Risks: There is no guarantee that Xenetic will successfully complete preclinical or clinical studies, obtain regulatory approval, or achieve commercial success with any current or future drug candidate.
• Intellectual Property and Competition: The company faces risks related to the protection and enforcement of its intellectual property, the potential invalidation of its patents, and competition from better-capitalized rivals or new technologies.
• Reliance on Collaborators and Third Parties: Xenetic’s reliance on partnerships and third parties for R&D and manufacturing requires sharing trade secrets, which increases the risk of misappropriation or disclosure, and exposes the company to the risk that collaborators may act in their self-interest.
• Shareholder Value Risks: The company’s preferred stockholders have rights that are preferential to those of common stockholders, which could result in diverging interests between different classes of shareholders.
• Market Volatility: The market price of Xenetic’s securities may be highly volatile, and activist shareholder actions could further impact management focus and company resources.

5. Shareholder and Stock Information

• Outstanding Shares: As of March 6, 2026, the number of outstanding shares of the company’s common stock was 2,291,056.
• Nasdaq Listing: Common stock is listed on the Nasdaq Capital Market under the symbol XBIO.
• Preferred Stock Outstanding: As of December 31, 2025, there were 1,454,545 shares of Series B Preferred Stock outstanding (down from 1,804,394 the prior year).

Potentially Price Sensitive Issues for Shareholders

• Strategic Review & Possible Transaction: The potential for a significant sale, merger, or similar transaction could dramatically alter the company’s structure, control, or valuation. Any announcement or failure regarding such a transaction may move the share price.
• Financing Needs and Dilution Risk: The need for substantial additional funding, with the possibility of further dilution or restrictive financing, is critical for shareholders to monitor.
• Nasdaq Listing Risk: Any movement towards delisting could severely impact share liquidity and value.
• Technology and Pipeline Risk: The commercial viability of the DNase platform technology is unproven and central to the company’s future.
• Uncertain Strategic Review Timeline and Outcome: The Board has not set a deadline for its review, and there is no assurance of any outcome or transaction.

Conclusion

Xenetic Biosciences, Inc. remains at a critical juncture. The company faces significant uncertainties relating to its strategic direction, funding requirements, and the development of its core technology platform. Investors should closely monitor announcements relating to the ongoing strategic review, funding activities, Nasdaq compliance, and progress (or setbacks) in development partnerships and clinical programs, as these represent major potential share price catalysts or risks.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should read the full Annual Report and consult with their own financial advisors prior to making any investment decisions. The information herein is based on company filings and is subject to change without notice. The author and publisher accept no liability for actions taken in reliance on this material.

View Xenetic Biosciences, Inc. Historical chart here